Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.

Herrán E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, Ugedo L, Pedraz JL, Lafuente JV, Hernández RM.

Int J Nanomedicine. 2014 May 27;9:2677-87. doi: 10.2147/IJN.S61940.

Protection by inosine in a cellular model of Parkinson's disease.

Cipriani S, Bakshi R, Schwarzschild MA.

Neuroscience. 2014 Aug 22;274:242-9. doi: 10.1016/j.neuroscience.2014.05.038.

The Relationships Between Poor Sleep Efficiency and Mild Cognitive Impairment in Parkinson Disease.

Gunn DG, Naismith SL, Terpening Z, Lewis SJ.

J Geriatr Psychiatry Neurol. 2014 Jun;27(2):77-84. doi: 10.1177/0891988713509135.

Parkinson's disease guidelines for pharmacists.

Patel T, Chang F; Parkinson Society Canada..

Can Pharm J (Ott). 2014 May;147(3):161-70. doi: 10.1177/1715163514529740. No abstract available.

VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.

Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, Fujikake N, Geisler S, Tabuchi M, Oshima R, Kikuchi A, Baba T, Wada K, Nagai Y, Takeda A, Aoki M.

Neurobiol Dis. 2014 Nov;71:1-13. doi: 10.1016/j.nbd.2014.07.014.

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker study.

Mehanna R, Scherzer CR, Ding H, Locascio JJ.

Neurology. 2014 May 6;82(18):1666; discussion 1666. doi: 10.1212/01.wnl.0000449750.81263.7d. No abstract available.

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.

Cáceres-Redondo MT, Carrillo F, Lama MJ, Huertas-Fernández I, Vargas-González L, Carballo M, Mir P.

J Neurol. 2014 Mar;261(3):561-9. doi: 10.1007/s00415-013-7235-1.

The association between ambient exposure to organophosphates and Parkinson's disease risk.

Wang A, Cockburn M, Ly TT, Bronstein JM, Ritz B.

Occup Environ Med. 2014 Apr;71(4):275-81. doi: 10.1136/oemed-2013-101394.

Corticomotor excitability in Parkinson's disease during observation, imagery and imitation of action: effects of rehabilitation using wii fit and comparison to healthy controls.

Esculier JF, Vaudrin J, Tremblay LE.

J Parkinsons Dis. 2014;4(1):67-75. doi: 10.3233/JPD-130212.

3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway.

Gunjima K, Tomiyama R, Takakura K, Yamada T, Hashida K, Nakamura Y, Konishi T, Matsugo S, Hori O.

J Cell Biochem. 2014 Jan;115(1):151-60. doi: 10.1002/jcb.24643.

Official Japanese Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale: validation against the original English version.

Kashihara K, Kondo T, Mizuno Y, Kikuchi S, Kuno S, Hasegawa K, Hattori N, Mochizuki H, Mori H, Murata M, Nomoto M, Takahashi R, Takeda A, Tsuboi Y, Ugawa Y, Yamanmoto M, Yokochi F, Yoshii F, Stebbins

Mov Disord Clin Pract. 2014 Sep 1;1(3):200-212.

Supporting people with Parkinson's in later life.

Hayes N, Surendranath S.

Nurs Older People. 2014 Oct;26(9):29-38. doi: 10.7748/nop.26.9.29.e620.

Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease.

Wu XL, Wang P, Liu YH, Xue YX.

J Mol Neurosci. 2014 May;53(1):1-9. doi: 10.1007/s12031-013-0175-5.

Influence of Deep Breathing on Heart Rate Variability in Parkinson's Disease: Co-relation with Severity of Disease and Non-Motor Symptom Scale Score.

Bidikar MP, Jagtap GJ, Chakor RT.

J Clin Diagn Res. 2014 Jul;8(7):BC01-3. doi: 10.7860/JCDR/2014/9470.4550.

Erratum: Dopaminergic therapy affects learning and impulsivity in Parkinson's disease.

[No authors listed]

Ann Clin Transl Neurol. 2014 Nov;1(11):953. doi: 10.1002/acn3.145.